Joint Programming Initiative on Antimicrobial Resistance (JPIAMR)
At a Glance
- Status: Active Consortium
- Year Launched: 2012
- Initiating Organization: European Commission Seventh Framework Programme (FP7)
- Initiator Type: Government
- Disease focus:
- Location: Europe
To achieve its mission of tackling antimicrobial resistance (AMR), the Joint Programme Initiative on Antimicrobial Resistance (JPIAMR) has identified six priority topics to form a strategic research agenda (SRA). These topics will equip the fight against antibiotic resistance with a multidimensional approach. This approach will be translated into new prevention and intervention strategies that improve public health and the well-being of populations and deliver economic and societal benefits throughout Europe and beyond. The SRA has adopted a One Health approach, including animals and the environment, in its AMR approach. Joint programming is the process by which participating countries define, develop, and implement a common strategic research agenda.
JPIAMR is composed of organizations from 19 countries. Its aim is to develop integrated approaches to pursue unique world-class research on AMR. The outcomes of this research will be translated into new prevention and intervention strategies to improve public health and well-being. It is expected that the results will also lead to economic and societal benefits not only in Europe but also globally.
JPIAMR will develop scientific proposals that will lead to sustainable use of antibiotics to treat infectious diseases and to a decrease in the number of patients with resistant infections in Europe. It aims to integrate relevant scientific fields across national borders and to create a common strategic research agenda with a shared common vision where the best resources and capabilities are coordinated.
JPIAMR provides the forum and platform for initiating and coordinating joint actions with stakeholders beyond issuing joint calls.
JPIAMR’s objectives are as follows:
Structure & Governance
The governance structure of JPIAMR includes a Management Board, Steering Committee, Scientific Advisory Board, Stakeholder Advisory Board, and Secretariat.
The Management Board (MB) is the main decision-making body, working according to the Terms of Reference. The MB meets on a regular basis and has met seven times since December 2010. Each participating country may nominate up to two MB members. The MB members must have a governmental mandate, and only one representative from each country may vote.
The Stakeholder Advisory Board (SHAB) held its first meeting in Brussels in April 2013. The following organizations agreed to participate:
Action on Antibiotic Resistance (ReAct)
European Federation of Pharmaceutical Industries Associations (EFPIA)
Federation of European Microbiological Societies (FEMS)
Federation of Veterinarians of Europe (FVE)
Standing Committee of European Doctors (CPME)
World Health Organization – Regional Office for Europe (WHO)
European Centre for Disease Prevention and Control (ECDC)
European Medicines Agency (EMA)
European Patient’s Forum (EPF)
European Society of Clinical Microbiology and Infectious Diseases (ESCMID)
European Food Safety Authority (EFSA)
JPIAMR’s first transnational call for research proposals resulted in seven consortia with partners from 11 different countries out of 40 submitted proposals. The total suggested funding is more than €8 million. The projects cover areas within prevention of infection, treatment (therapy) development, drug development, target identification for antibacterial drug development, and pharmacokinetics.
Points of Contact
Sponsors & Partners
JPIAMR includes 19 Member States: Belgium, Canada, Czech Republic, Denmark, Finland, France, Germany, Greece, Israel, Italy, Netherlands, Norway, Poland, Romania, Spain, Sweden, Switzerland, Turkey, and the United Kingdom
Agence Nationale de la Recherche
Autoritatea Nationala Pentru Cercetare Stiintifica
Forschungszentrum Juelich GMBH
Institut National de la Sante Et de la Recherche Medicale (INSERM)
Instituto de Salud Carlos III
Medical Research Council
Ministry of Health
Vetenskapsrådet – Swedish Research Council
Zorgonderzoek Nederland Zon